Profluent leverages AI for groundbreaking medicine discovery, supported by Salesforce research and investment from Jeff Dean.
Main Points:
- Profluent’s Genesis: Stemming from Salesforce’s ProGen project, Profluent aims to transform the drug development process by designing custom-fit treatments using generative AI.
- Technology and Goals: By analyzing the language of proteins, Profluent intends to create new proteins and gene-editing technologies, aiming for solutions that are specifically tailored to individual patient needs.
- Industry Impact and Future Plans: Profluent’s approach could significantly reduce the time and cost associated with drug development, with the support of notable investors and the tech community.
Summary:
Profluent emerges from the Salesforce-initiated ProGen project, spearheaded by Ali Madani, to revolutionize the way medicines are discovered using AI. Unlike traditional methods, Profluent focuses on starting with patient and therapeutic needs to backward engineer treatments. This innovative method could potentially uncover medical treatments more efficiently and cost-effectively. Profluent, with its advanced AI technologies, is set to collaborate with pharmaceutical companies to create “genetic medicines” that are a perfect fit for patient-specific requirements, a significant deviation from the hit-and-miss approach of traditional drug discovery.
The technology behind Profluent is deeply rooted in the analysis of proteins as a language, allowing for the prediction and creation of new proteins with novel functions. This forward-thinking approach is not only about improving existing gene-editing tools but also about pioneering entirely new ways of treating genetic diseases through optimized, custom-designed gene editors. With substantial backing from venture capitalists and industry leaders like Jeff Dean, Profluent stands at the forefront of a significant shift towards intentional, AI-driven design of medicines. As it moves to expand its AI models and data sets, Profluent is preparing to scale its solutions in partnership with others in the field, aiming to outpace competitors and redefine the landscape of medicine development.
Source: Profluent, spurred by Salesforce research and backed by Jeff Dean, uses AI to discover medicines
Keep up to date on the latest AI news and tools by subscribing to our weekly newsletter, or following up on Twitter and Facebook.
